-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Cytek Biosciences, Raises Price Target to $7

Benzinga·11/10/2026 14:09:10
Listen to the news
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $6 to $7.